secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001140361-24-035211
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech aligns with FDA on Phase 3 VERSATILE-003 trial for HPV16-positive HNSCC; initiation in Q4 2024
--------------------------------------------------------------------------------

- Received official FDA minutes supporting Phase 3 trial of Versamune HPV + pembrolizumab for first-line recurrent/metastatic HPV16-positive HNSCC.
- FDA agreed to separate PDS01ADC dose optimization to avoid delay; VERSATILE-003 proceeds as a 2-arm double combination registrational trial.
- Phase 3 VERSATILE-003 trial to begin enrollment in Q4 2024; primary endpoint is overall survival.
- Versamune HPV + pembrolizumab combination holds FDA Fast Track designation for this indication.
- Corporate presentation updated; management cites matured VERSATILE-002 survival data supporting revised statistical endpoints.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124035211/0001140361-24-035211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124035211/ef20033424_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-035211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer